ADAPTIVE BIOTECHNOLOGIES CORPORATION Interest Expense
ADAPTIVE BIOTECHNOLOGIES CORPORATION (ADPT) reported Interest Expense of $2.69 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement
us-gaap:InterestExpense · last filed 2026-08-04
- ADAPTIVE BIOTECHNOLOGIES CORPORATION interest expense for the quarter ending 2026-06-30 was $2.69M, a 8.62% decline year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION interest expense for the quarter ending 2026-03-31 was $2.89M, a 0.55% decline year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION interest expense for the quarter ending 2025-12-31 was $2.95M, a 0.07% increase year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION interest expense for the quarter ending 2025-09-30 was $2.97M, a 1.09% increase year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION interest expense for fiscal 2025 was $11.78M, a 1.71% increase from fiscal 2024.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION interest expense for fiscal 2024 was $11.58M, a 16.09% decline from fiscal 2023.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION interest expense for fiscal 2023 was $13.80M, a 225.63% increase from fiscal 2022.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION interest expense for fiscal 2022 was $4.24M.
| Period end | Interest Expense 3 month | Interest Expense 6 month | Interest Expense 9 month | Interest Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.69M 10-Q · filed 2026-08-04 | $5.58M 10-Q · filed 2026-08-04 | $8.54M derived: sum of 3 quarters · filed 2026-08-04 | $11.51M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $2.89M 10-Q · filed 2026-05-05 | $5.84M derived: sum of 2 quarters · filed 2026-05-05 | $8.81M derived: sum of 3 quarters · filed 2026-05-05 | $11.76M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $2.95M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $5.92M derived: sum of 2 quarters · filed 2026-02-26 | $8.87M derived: sum of 3 quarters · filed 2026-08-04 | $11.78M 10-K · filed 2026-02-26 |
| 2025-09-30 | $2.97M 10-Q · filed 2025-11-05 | $5.92M derived: sum of 2 quarters · filed 2026-08-04 | $8.82M 10-Q · filed 2025-11-05 | $11.78M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $2.95M 10-Q · filed 2026-08-04 | $5.85M 10-Q · filed 2026-08-04 | $8.80M derived: sum of 3 quarters · filed 2026-08-04 | $11.74M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $2.90M 10-Q · filed 2026-05-05 | $5.86M derived: sum of 2 quarters · filed 2026-05-05 | $8.80M derived: sum of 3 quarters · filed 2026-05-05 | $11.49M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $2.95M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $5.89M derived: sum of 2 quarters · filed 2026-02-26 | $8.59M derived: sum of 3 quarters · filed 2026-02-26 | $11.58M 10-K · filed 2026-02-26 |
| 2024-09-30 | $2.94M 10-Q · filed 2025-11-05 | $5.63M derived: sum of 2 quarters · filed 2025-11-05 | $8.63M 10-Q · filed 2025-11-05 | $11.64M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $2.70M 10-Q · filed 2025-08-05 | $5.69M 10-Q · filed 2025-08-05 | $8.70M derived: sum of 3 quarters · filed 2026-02-26 | $12.35M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $2.99M 10-Q · filed 2025-05-01 | $6.00M derived: sum of 2 quarters · filed 2026-02-26 | $9.66M derived: sum of 3 quarters · filed 2026-02-26 | $13.26M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $3.01M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $6.66M derived: sum of 2 quarters · filed 2026-02-26 | $10.27M derived: sum of 3 quarters · filed 2026-02-26 | $13.80M 10-K · filed 2026-02-26 |
| 2023-09-30 | $3.65M 10-Q · filed 2024-11-07 | $7.26M derived: sum of 2 quarters · filed 2024-11-07 | $10.79M 10-Q · filed 2024-11-07 | $14.37M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $3.60M 10-Q · filed 2024-08-01 | $7.14M 10-Q · filed 2024-08-01 | $10.72M derived: sum of 3 quarters · filed 2025-03-03 | $11.37M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | $3.53M 10-Q · filed 2024-05-07 | $7.12M derived: sum of 2 quarters · filed 2025-03-03 | $7.77M derived: sum of 3 quarters · filed 2025-03-03 | |
| 2022-12-31 | $3.58M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $4.24M derived: sum of 2 quarters · filed 2025-03-03 | $4.24M 10-K · filed 2025-03-03 | |
| 2022-09-30 | $653.00K 10-Q · filed 2023-11-09 | $653.00K 10-Q · filed 2023-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |